Download PDF
Thromb Haemost 2008; 100(01): 149-150
DOI: 10.1160/TH07-06-0422
Case Report
Schattauer GmbH

Temporarily successful eradication therapy in acquired haemophilia with high inhibitor titer: A case report with a new protocol

Péter Ilonczai
1   University of Debrecen, Medical and Health Science Center, 2nd Department of Medicine, Division of Haemostasis, Debrecen, Hungary
,
Ágota Schlammadinger
1   University of Debrecen, Medical and Health Science Center, 2nd Department of Medicine, Division of Haemostasis, Debrecen, Hungary
,
Zsolt Oláh
1   University of Debrecen, Medical and Health Science Center, 2nd Department of Medicine, Division of Haemostasis, Debrecen, Hungary
,
Katalin Rázsó
1   University of Debrecen, Medical and Health Science Center, 2nd Department of Medicine, Division of Haemostasis, Debrecen, Hungary
,
Zsuzsanna Bereczky
2   Clinical Research Center, Debrecen, Hungary
,
Zoltán Boda
1   University of Debrecen, Medical and Health Science Center, 2nd Department of Medicine, Division of Haemostasis, Debrecen, Hungary
› Author Affiliations
Further Information

Publication History

Received 22 June 2007

Accepted after major revision 13 May 2008

Publication Date:
22 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Kessler CM, Nemes L. Acquired inhibitors to factor VIII. Inhibitors in Patients with Haemophilia. Great Britain: Blackwell Science; 2002: 98-112.
    Google Scholar
  • 2 Lavigne-Lissalde G, Schved JF, Granier C. et al. Anti-factor VIII antibodies. Thromb Haemost 2005; 94: 760-769.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Hay CRM, Brown S, Collins PW. et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Brit J Haematol 2006; 133: 591-605.
    CrossrefPubMedGoogle Scholar
  • 4 Holme PA, Brosstad F, Tjonnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005; 11: 510-515.
    CrossrefPubMedGoogle Scholar
  • 5 Herbst KD, Rapaport SI, Kenoyer DG. et al. Syndrome of an acquired inhibitor of factor VIII responsive to cyclophosphamide and prednisone. Ann Int Med 1981; 95: 575-578.
    CrossrefPubMedGoogle Scholar
  • 6 Brackmann HH, Wallny T. Immune tolerance: high-dose regimen. Inhibitors in Patients with Haemophilia. Great Britain: Blackwell Science; 2002: 45-48.
    Google Scholar
  • 7 Collins PW. Treatment of acquired haemophilia A. J Thromb Haemost 2007; 05: 893-900.
    CrossrefPubMedGoogle Scholar
  • 8 Hausl C, Ahmad RU, Sassgary M. et al. High dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 2005; 106: 3415-3422.
    CrossrefPubMedGoogle Scholar
  • 9 Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica 2000; 85: 64-68.
    PubMedGoogle Scholar
  • 10 Pfliegler G, Boda Z, Hársfalvi J. et al. Cyclosporine treatment of a woman with acquired haemophilia dueto factor VIII:C inhibitor. Postgrad Med J 1989; 65: 400-402.
    CrossrefPubMedGoogle Scholar
  • 11 Pardos-Gea J, Ordi-Ros J, Altisent C. et al. Acquired haemophilia A: Successful treatment with immunosuppression, methylprednisone pulses and oral cyclosporine. Thromb Haemost 2006; 95: 735-737.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Au WY, Lam CC, Kwong YL. Successful treatment of acquired factor VIII inhibitor with cyclosporine. Haemophilia 2004; 10: 98-100.
    CrossrefPubMedGoogle Scholar
  • 13 Sperr WR, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 2007; 92: 66-71.
    CrossrefPubMedGoogle Scholar
  • 14 Onitilo AA, Skorupa A, Lal A. et al. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost 2006; 96: 84-87.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Stasi R, Brunetti M, Stipa E. et al. Successful B-cell depletion with rituximab for the treatment of patients with acquired haemophilia. Blood 2004; 103: 4424-4428.
    CrossrefPubMedGoogle Scholar
  • 16 Lian EC-Y, Larcada AF, Chiu AY-Z. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Int Med 1989; 110: 774-778.
    CrossrefPubMedGoogle Scholar
  • 17 Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005; 16: 27-31.
    CrossrefPubMedGoogle Scholar
  • 18 Barillé-Nion S, Barlogie B, Bataille R. et al. Advances in biology and therapy of multiple myeloma. Haematology. American Society of Haematology; 2003: 248-278.
    Google Scholar
  • 19 Reece DE. An update of the management of multiple myeloma: the changing landscape. Haematology. American Society of Haematology; 2005: 353-359.
    Google Scholar